DrugPatentWatch Database Preview

Details for Patent: 6,488,962

« Back to Dashboard

Which drugs does patent 6,488,962 protect, and when does it expire?

Patent 6,488,962 protects GLUMETZA, JENTADUETO XR, PROQUIN XR, SYNJARDY XR, XARTEMIS XR, and GRALISE, and is included in six NDAs.

This patent has nineteen patent family members in fourteen countries.

Summary for Patent: 6,488,962

Title:	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Abstract:	The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
Inventor(s):	Berner; Bret (El Granada, CA), Louie-Helm; Jenny (Union City, CA)
Assignee:	DepoMed, Inc. (Menlo Park, CA)
Application Number:	09/598,061
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,488,962
Patent Claim Types: see list of patent claims	Dosage form;

Drugs Protected by US Patent 6,488,962

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-001	Jun 3, 2005	AB3	RX	Yes	No			Y	Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No			Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes			Y
Depomed Inc	PROQUIN XR	ciprofloxacin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021744-001	May 19, 2005		DISCN	No	No			Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No			Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No			Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-003	Dec 9, 2016		RX	Yes	No			Y

International Family Members for US Patent 6,488,962

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	256455
Australia	2001239893
Australia	3989301
Canada	2412671
Germany	60101581
Denmark	1294363
European Patent Office	1294363